"CTLA-4 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An inhibitory T CELL receptor that is closely related to CD28 ANTIGEN. It has specificity for CD80 ANTIGEN and CD86 ANTIGEN and acts as a negative regulator of peripheral T cell function. CTLA-4 antigen is believed to play role in inducing PERIPHERAL TOLERANCE.
| Descriptor ID |
D060908
|
| MeSH Number(s) |
D12.776.543.750.705.222.750 D23.050.301.264.894.158 D23.101.100.894.158
|
| Concept/Terms |
CTLA-4 Antigen- CTLA-4 Antigen
- Antigen, CTLA-4
- CTLA 4 Antigen
- Antigens, CD152
- CD152 Antigens
- Cytotoxic T-Lymphocyte-Associated Antigen 4
- Cytotoxic T Lymphocyte Associated Antigen 4
- Cytotoxic T-Lymphocyte Antigen 4
- Cytotoxic T Lymphocyte Antigen 4
- CD152 Antigen
- Antigen, CD152
|
Below are MeSH descriptors whose meaning is more general than "CTLA-4 Antigen".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptors, Immunologic [D12.776.543.750.705]
- Costimulatory and Inhibitory T-Cell Receptors [D12.776.543.750.705.222]
- CTLA-4 Antigen [D12.776.543.750.705.222.750]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Surface [D23.050.301]
- Antigens, Differentiation [D23.050.301.264]
- Antigens, Differentiation, T-Lymphocyte [D23.050.301.264.894]
- CTLA-4 Antigen [D23.050.301.264.894.158]
- Biomarkers [D23.101]
- Antigens, Differentiation [D23.101.100]
- Antigens, Differentiation, T-Lymphocyte [D23.101.100.894]
- CTLA-4 Antigen [D23.101.100.894.158]
Below are MeSH descriptors whose meaning is more specific than "CTLA-4 Antigen".
This graph shows the total number of publications written about "CTLA-4 Antigen" by people in this website by year, and whether "CTLA-4 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2005 | 0 | 2 | 2 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 4 | 4 |
| 2009 | 0 | 2 | 2 |
| 2010 | 0 | 6 | 6 |
| 2011 | 0 | 3 | 3 |
| 2012 | 2 | 2 | 4 |
| 2014 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 3 | 2 | 5 |
| 2018 | 3 | 0 | 3 |
| 2019 | 0 | 4 | 4 |
| 2020 | 2 | 2 | 4 |
| 2021 | 2 | 1 | 3 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 2 | 2 |
| 2024 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "CTLA-4 Antigen" by people in Profiles.
-
Comparing neoantigen cancer vaccines and immune checkpoint therapy unveils an effective vaccine and anti-TREM2 macrophage-targeting dual therapy. Cell Rep. 2024 11 26; 43(11):114875.
-
Assessing clonal changes in T?cells over time following immunotherapy is a breeze with Cyclone. Cancer Cell. 2024 Sep 09; 42(9):1491-1493.
-
ICOS costimulation in combination with CTLA-4 blockade remodels tumor-associated macrophages toward an antitumor phenotype. J Exp Med. 2024 Apr 01; 221(4).
-
Activated phosphoinositide 3-kinase d syndrome: Update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity. J Allergy Clin Immunol. 2023 10; 152(4):984-996.e10.
-
A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma. Clin Cancer Res. 2023 02 01; 29(3):548-559.
-
LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockade. J Clin Invest. 2022 07 01; 132(13).
-
Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males. J Transl Med. 2022 06 03; 20(1):253.
-
Characterization of T cell responses to co-administered hookworm vaccine candidates Na-GST-1 and Na-APR-1 in healthy adults in Gabon. PLoS Negl Trop Dis. 2021 10; 15(10):e0009732.
-
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat Med. 2021 08; 27(8):1432-1441.
-
CTLA-4 blockade and interferon-a induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma. PLoS One. 2021; 16(1):e0245287.